Laia Paré

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

43h-index7.1kcitations430works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(170), Advanced Breast Cancer Therapies(132), Breast Cancer Treatment Studies(131), Cancer Treatment and Pharmacology(72), Cancer Genomics and Diagnostics(68)

Publications430 total

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Clinical Cancer Research·2025Open Access
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
UNC Libraries·2025Open Access
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
UNC Libraries·2025Open Access
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
UNC Libraries·2025Open Access
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
Nature Communications·2025· 1 citedOpen Access
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
ESMO Open·2025· 2 citedOpen Access
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
The Lancet Oncology·2025· 11 cited
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer
JNCI Journal of the National Cancer Institute·2025
Abstract P5-07-18: HER2DX assay in HER2-positive (HER2+) breast ductal carcinoma in situ (DCIS)
Clinical Cancer Research·2025
Abstract PS4-10: TNBC-DX Genomic Test Predicts High pCR in Triple-Negative Breast Cancer with sTILs ≥30% Treated with Neoadjuvant Docetaxel-Carboplatin with/without Pembrolizumab
Clinical Cancer Research·2025
Abstract P4-03-19: Plasma-based prediction of prognosis, receptor status and organ involvement among patients receiving antibody-drug conjugates for metastatic breast cancer
Clinical Cancer Research·2025· 1 cited
Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial
Clinical Cancer Research·2025
Abstract PS4-06: HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab: Correlative Analysis from CLEOPATRA Phase III Trial
Clinical Cancer Research·2025· 1 cited
Abstract PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial
Clinical Cancer Research·2025
HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
Journal of Clinical Oncology·2025
Association of immune, proliferation gene signatures and stromal tumor infiltrating lymphocytes (sTILs) with outcomes in patients with stage I triple-negative breast cancer (TNBC).
Journal of Clinical Oncology·2025
Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).
Journal of Clinical Oncology·2025· 2 cited
Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
Translational Oncology·2025· 1 citedOpen Access
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
npj Breast Cancer·2025· 4 citedOpen Access
Abstract 5867: Uncovering T-cell receptor clones and immunogenic targets in HER2DX-defined HER2-positive breast cancer
Cancer Research·2025
page 1 of 22Next →

Frequent Co-authors

Aleix Prat(37), Tomás Pascual(21), Patricia Galván(21), María Vidal(17), Bárbara Adamo(16), Montserrat Muñoz-Mateu(16), Eduardo Martínez de Dueñas(15), Patricia Villagrasa(14), Fara Brasó‐Maristany(12), Núria Chic(11), Blanca González‐Farré(11), Paolo Nucíforo(11), Antonio Llombart‐Cussac(11), Javier Cortés(11), Mafalda Oliveira(11), Eva Ciruelos(11), Sònia Pernas(9), Joel S. Parker(8), Charles M. Perou(8), Gaia Griguolo(8)